500124 logo

Dr. Reddy's Laboratories Limited Stock Price

BSE:500124 Community·₹978.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 36 Fair Values set on narratives written by author

500124 Share Price Performance

₹0
-1200.75 (-100.00%)
₹1,265.77
Fair Value
₹0
-1200.75 (-100.00%)
Price ₹0

500124 Community Narratives

·
Fair Value ₹1.27k 7.4% undervalued intrinsic discount

Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
·
Fair Value ₹1.6k 26.8% undervalued intrinsic discount

Global Aging Trends Will Expand Biosimilars And Generics Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value ₹1.04k 12.7% overvalued intrinsic discount

Intensifying Pricing Pressures And Regulatory Crackdowns Will Erode Future Profitability

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
₹1.6k
26.8% undervalued intrinsic discount
Revenue
16.39% p.a.
Profit Margin
15.92%
Future PE
22.94x
Price in 2029
₹2.28k

Trending Discussion

No trending discussion available.

Updated Narratives

500124 logo

500124: Fair Outlook Will Balance New Drug Launches And Compliance Developments

Fair Value: ₹1.27k 7.4% undervalued intrinsic discount
16 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
500124 logo

500124: New Biologics And Diabetes Launches Will Drive Future Upside

Fair Value: ₹1.6k 26.8% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
500124 logo

500124: Lower Profitability Expectations Will Restrain Future Share Price Upside

Fair Value: ₹1.04k 12.7% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet, undervalued and pays a dividend.

1 Risk
4 Rewards

Dr. Reddy's Laboratories Limited Key Details

₹331.2b

Revenue

₹165.0b

Cost of Revenue

₹166.2b

Gross Profit

₹133.1b

Other Expenses

₹33.1b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
39.75
50.18%
10.00%
14.9%
View Full Analysis

About 500124

Founded
1984
Employees
27527
CEO
Erez Israeli
WebsiteView website
www.drreddys.com

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Recent 500124 News & Updates

Narrative Update Aug 06

500124: Fair Outlook Will Balance New Drug Launches And Compliance Developments

Analysts now place fair value for Dr. Reddy's Laboratories at about ₹1,266, compared with the prior estimate of roughly ₹1,332. The revision reflects updated assumptions for slightly higher revenue growth, a marginally lower discount rate and a more conservative future P/E multiple.

Recent updates

No updates